IRIS
PEPE, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.723
NA - Nord America 3.922
EU - Europa 3.526
SA - Sud America 587
Continente sconosciuto - Info sul continente non disponibili 224
AF - Africa 86
OC - Oceania 7
Totale 14.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.733
SG - Singapore 2.514
RU - Federazione Russa 1.394
IT - Italia 1.181
CN - Cina 1.115
VN - Vietnam 817
HK - Hong Kong 496
BR - Brasile 470
DE - Germania 222
BD - Bangladesh 213
FR - Francia 177
IN - India 142
NL - Olanda 119
KR - Corea 100
CA - Canada 99
GB - Regno Unito 96
JP - Giappone 91
ES - Italia 63
FI - Finlandia 62
AR - Argentina 52
MX - Messico 51
UA - Ucraina 41
IQ - Iraq 39
PH - Filippine 37
PL - Polonia 25
IE - Irlanda 24
SE - Svezia 22
ZA - Sudafrica 21
EC - Ecuador 20
ID - Indonesia 20
TH - Thailandia 20
AT - Austria 15
PK - Pakistan 15
TR - Turchia 15
CI - Costa d'Avorio 13
LT - Lituania 12
TW - Taiwan 12
VE - Venezuela 12
CR - Costa Rica 10
EG - Egitto 10
NP - Nepal 10
UZ - Uzbekistan 10
CH - Svizzera 8
CO - Colombia 8
GR - Grecia 8
JM - Giamaica 8
RO - Romania 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
BE - Belgio 7
JO - Giordania 7
MA - Marocco 7
PY - Paraguay 7
RS - Serbia 7
SA - Arabia Saudita 7
BG - Bulgaria 6
MY - Malesia 6
PE - Perù 6
DZ - Algeria 5
PT - Portogallo 5
UY - Uruguay 5
AL - Albania 4
AU - Australia 4
CL - Cile 4
KE - Kenya 4
KZ - Kazakistan 4
NI - Nicaragua 4
BO - Bolivia 3
BS - Bahamas 3
EE - Estonia 3
ET - Etiopia 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
IL - Israele 3
PS - Palestinian Territory 3
SC - Seychelles 3
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GA - Gabon 2
HN - Honduras 2
HU - Ungheria 2
KW - Kuwait 2
LY - Libia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
BF - Burkina Faso 1
BW - Botswana 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
Totale 13.832
Salva come PNG Salva come JPEG
Città #
Singapore 1.262
San Jose 743
Hong Kong 483
Hefei 437
Ashburn 395
Moscow 338
Chandler 282
Beijing 253
Ho Chi Minh City 245
Hanoi 181
Naples 178
Santa Clara 143
Milan 128
Lauterbourg 121
Los Angeles 111
The Dalles 101
Rome 88
Seoul 83
Tokyo 81
Munich 80
New York 75
Kochi 70
Buffalo 68
Millbury 62
São Paulo 60
Dallas 58
Lawrence 56
Redondo Beach 54
Des Moines 47
Amsterdam 46
Haiphong 41
Napoli 40
Boston 34
Helsinki 34
Council Bluffs 32
Da Nang 31
Valencia 30
Orem 28
Boardman 26
Frankfurt am Main 26
Mexico City 25
Montreal 24
Wilmington 24
London 23
Seattle 23
Toronto 23
Atlanta 21
Baghdad 19
Bologna 19
Brooklyn 19
Warsaw 19
Chicago 18
Falkenstein 18
Rio de Janeiro 18
Houston 17
Turin 17
Bari 16
Denver 16
Guangzhou 16
Nuremberg 16
Phoenix 16
Turku 16
Biên Hòa 15
Chennai 14
Florence 14
Nanjing 14
Ottawa 14
Stockholm 14
Hải Dương 13
San Francisco 13
Shanghai 13
Dublin 12
Fairfield 12
Can Tho 11
Genoa 11
Belo Horizonte 10
Johannesburg 10
Madrid 10
Memphis 10
Palermo 10
Bangkok 9
Curitiba 9
Princeton 9
Quito 9
Salt Lake City 9
Tashkent 9
Brasília 8
Buenos Aires 8
Lappeenranta 8
Miami 8
Philadelphia 8
Tianjin 8
Trieste 8
Aversa 7
Bexley 7
Düsseldorf 7
Krefeld 7
New Delhi 7
Ninh Bình 7
Poplar 7
Totale 7.453
Salva come PNG Salva come JPEG
Nome #
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples 224
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 195
Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. 189
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients 172
Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens 170
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. 166
Technical Validation of a Fully Integrated NGS Platform in the Real-World Practice of Italian Referral Institutions 165
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience 165
Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study 158
Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study 153
Liquid biopsy as indication of tumour progression in lung cancer: A potential intervention in tertiary prevention 153
Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions 149
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 148
ALK and ROS1 testing on lung cancer cytologic samples: Perspectives 146
RNA-based next generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 143
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 142
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer 139
Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx 138
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma 137
Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer 136
Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study 136
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 135
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients 135
Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics 135
Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: A retrospective study 134
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 133
Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models. 133
The role of liquid biopsy in epithelial ovarian cancer: state of the art 132
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens 132
Next generation sequencing in cytology 132
Predictive molecular pathology in the time of COVID-19 130
Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel 130
Methods for actionable gene fusion detection in lung cancer: now and in the future 130
KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting 128
Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: Preliminary results from a prospective study 127
Liquid Biopsy in Prostate Cancer Management{\textemdash}Current Challenges and Future Perspectives 127
EGFR mutation detection by microfluidic technology: a validation study. 127
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 127
Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas 126
Brca1/2 ngs somatic testing in clinical practice: a short report 125
The evolving role of liquid biopsy in lung cancer 124
Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting 123
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 122
Tumor mutational burden on cytological samples: A pilot study 122
Osimertinib 121
Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer 121
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 120
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer 120
EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing 119
BRAF: A Two-Faced Janus 119
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 118
BRAF mutations in lung cancer 118
Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations 118
Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer 116
Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours 115
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 114
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy 114
EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: A case report and literature review 113
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 113
Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment 112
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective 112
Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre 112
Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment 111
An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples 109
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify® Mutation Profiler 109
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 108
Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study 108
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy 107
TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study 106
Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature 105
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls 104
MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice 102
The Impact of potential ‘confounders’ on the diagnostic sensitivity of circulating free DNA in management of FIT+ patients: a pilot study 100
Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report 100
Liquid biopsy testing in urological cancers: Focus on urine 99
Genomics and the early diagnosis of lung cancer 98
The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response 95
Harmonization trial on ESR1 testing strategies in ER+/HER2- breast cancer patients: an Italian experience 95
Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective 94
Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications 92
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: practical indications from an Italian multidisciplinary group 90
Microsatellite instability evaluation by automated microfluidic electrophoresis: an update 88
Critical aspects of MSI testing in endometrial cancer: a comparison study 85
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 85
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 85
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 85
Smaller, cheaper, faster: where next for liquid biopsies? 82
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 81
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers 80
Uterine Tumours Resembling Ovarian Sex-Cord Tumors: A Case Report and Review of the Literature 79
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors 78
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens 78
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 78
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice 78
Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches 77
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study 76
Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution 76
Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer 75
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy 74
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: are we on the right path? 74
Totale 11.834
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022412 0 13 11 4 5 11 3 50 17 47 117 134
2022/2023714 80 52 31 44 89 88 2 82 119 48 69 10
2023/2024584 23 97 42 24 37 39 19 63 18 55 99 68
2024/20253.547 164 176 13 34 87 152 355 226 254 463 1.244 379
2025/20268.103 742 818 828 736 1.245 351 784 497 899 476 281 446
2026/2027263 232 31 0 0 0 0 0 0 0 0 0 0
Totale 14.075